The therapeutic potential of inorganic polyphosphate: A versatile physiological polymer to control coronavirus disease (COVID-19)
Open Access
- 1 January 2021
- journal article
- review article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 11 (13) , 6193-6213
Abstract
Rationale: The pandemic caused by the novel coronavirus SARS-CoV-2 is advancing rapidly. In particular, the number of severe courses of the disease is still dramatically high. An efficient drug therapy that helps to improve significantly the fatal combination of damages in the airway epithelia, in the extensive pulmonary microvascularization and finally multiorgan failure, is missing. The physiological, inorganic polymer, polyphosphate (polyP) is a molecule which could prevent the initial phase of the virus life cycle, the attachment of the virus to the target cells, and improve the epithelial integrity as well as the mucus barrier.Keywords
This publication has 161 references indexed in Scilit:
- Mucin dynamics and enteric pathogensNature Reviews Microbiology, 2011
- A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus EntryJournal of Virology, 2011
- Intranasal Delivery of an IgA Monoclonal Antibody Effective against Sublethal H5N1 Influenza Virus Infection in MiceClinical and Vaccine Immunology, 2010
- Membrane-tethered mucins have multiple functions on the ocular surfaceExperimental Eye Research, 2010
- Platelet Polyphosphates Are Proinflammatory and Procoagulant Mediators In VivoCell, 2009
- Purinergic receptors in airway epitheliaCurrent Opinion in Pharmacology, 2009
- Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissuesAdvanced Drug Delivery Reviews, 2009
- Functions of ocular surface mucins in health and diseaseCurrent Opinion in Allergy and Clinical Immunology, 2008
- Mathematical Model of Nucleotide Regulation on Airway EpitheliaJournal of Biological Chemistry, 2008
- E-NTPDases in human airways: Regulation and relevance for chronic lung diseasesPurinergic Signalling, 2006